CNBG · ToCell

Supporting China's Biopharmaceutical Process Engineering Technology

  CNBG ToCell (Wuxi) Biotechnology Co., Ltd., a leading provider of advanced biopharmaceutical process engineering technologies and solutions in China, is dedicated to enhancing the nation’s independent control over upstream raw materials and equipment, accelerating growth and self-sufficiency across the biopharmaceutical industry. We focus on customized cell culture medium and paper-based carrier research and production, large-scale bioreactor design and manufacturing, animal cell culture technology, and bioprocess technology development and transfer, forming the foundation of a robust biopharmaceutical process technology platform.

 

  Suzhou ToCell Biotechnology Co., Ltd., a wholly-owned subsidiary of CNBG ToCell (Wuxi) Biotechnology Co., Ltd., is located in the Wujiang Economic and Technological Development Zone in Suzhou, spanning 8,000 m2. The site includes GMP-compliant, 5,000-m2 production facilities and R&D laboratories dedicated to cell culture medium, paper-based carriers, and bioreactors. ToCell is certified as a national high-tech enterprise and complies with standards of ISO9001 quality management system, ISO13485 medical device quality management system, ISO14001 environmental management system, and ISO45001 occupational health and safety management system. With an annual production capacity of 150 tons of cell culture medium and over 100 bioreactors, we are well-equipped to support the biopharmaceutical industry’s rapid and evolving needs, including applications in antibodies, vaccines, and cell therapy.

CNBG · ToCell

CNBG · ToCell

CNBG · ToCell

CNBG · ToCell

CNBG · ToCell

CNBG · ToCell

2014 years

Be established in

8000

Company floor space

150 ton

Annual capacity

100 +

Annual output